TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06390826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00110188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Study: NCT00793520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Twice daily oral administration of Milnacipran for 5 weeks.
Study: NCT03128684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Green Lentil Muffin
Description: Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split Red Lentil Muffin
Description: Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Muffin
Description: Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Green Lentil Chili
Description: Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
Study: NCT02000102

Intervention type: DRUG
Intervention: Intravitreal Injection of Aflibercept
Study: NCT06390826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study: NCT01300026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 319
Description: AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 319
Description: AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
Study: NCT03128684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split Red Lentil Chili
Description: Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Chili
Description: Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
Study: NCT00690482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, twice daily
Study: NCT06390826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study: NCT00690482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral tablet, twice daily
Study: NCT03441295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization
Description: DIS, Ligamys

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Brace Ligament Augmentation
Description: IBLA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Brace Ligament Augmentation
Description: IBLA
Study: NCT01090596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg naproxen, twice daily for 7 days
Study: NCT03441295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: Conventional
Study: NCT01132664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
Study: NCT02618486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: NSPT includes oral hygiene education, scaling root planing and mouth wash
Study: NCT01090596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab,twice a day for a seven days
Study: NCT01212900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins, HMG CoA
Description: Statin therapy
Study: NCT02618486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: NSPT includes oral hygiene education, scaling root planing and mouth wash
Study: NCT01132664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
Study: NCT04477551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser (device) with scaling and root planing
Description: Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional scaling and root planing
Description: Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
Study: NCT01212900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins, HMG CoA
Description: Statin therapy
Study: NCT00418522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin (Exubera)
Description: Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Study: NCT01282541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
Study: NCT02911727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-track discharge
Description: As described above
Study: NCT03890211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Electric Infant Warmer
Description: Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
Study: NCT00919984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP chemotherapy
Description: IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
Study: NCT00483548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
Study: NCT00005835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buthionine sulfoximine
Description: Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell infusion
Description: Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
Study: NCT02297516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure or Dysport
Description: Glabellar lines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure or Dysport
Description: Glabellar lines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane or Emervel filler
Description: Facial tissue augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane or Emervel filler
Description: Facial tissue augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinbooster
Description: Facial skin rejuvenation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinbooster
Description: Facial skin rejuvenation
Study: NCT02835690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03968874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box therapy
Description: The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Negative Ion Generator
Description: The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
Study: NCT04490278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Record Review - Inpatient Treatment
Description: Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Questionnaires
Description: Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
Study: NCT00366457

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Study: NCT03538912

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker strategy
Description: EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine strategy
Description: EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
Study: NCT02035969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment Support (ETS)
Description: Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup.
Study: NCT06315933

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia inluding inhaled and intravenous

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia inluding inhaled and intravenous
Study: NCT02602106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic activities intervention
Description: Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
Study: NCT01001078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel supraglottic airway device
Description: 2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme supraglottic airway device
Description: In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endotracheal tube
Description: In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endotracheal tube
Description: In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endotracheal tube
Description: In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
Study: NCT03371966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Nitrate Beetroot Juice
Description: High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Nitrate Beetroot Juice
Description: Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
Study: NCT02104765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously.
Study: NCT01441960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
Study: NCT00483548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
Study: NCT02339610

Intervention type: DEVICE
Intervention: ATTUNE Primary, Cemented Total Knee Replacement
Description: Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
Study: NCT04265690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking classes
Description: Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
Study: NCT02231424

Intervention type: DRUG
Intervention: Drug: Berodual®
Study: NCT04274582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chokeberry extract
Description: The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
Study: NCT01239472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
Study: NCT00860691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic conventional colorectal surgery
Description: Patients with colorectal cancer undergo open laparotomy and colorectal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic laparoscopic colorectal surgery
Description: Patients with colorectal cancer undergo laparoscopic colorectal resection

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest
Description: Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
Study: NCT02104765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously.
Study: NCT00836719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
Study: NCT02401477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole + Amoxicillin
Description: Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
Study: NCT02823730

Intervention type: OTHER
Intervention: PCI with Synergy Stent
Description: 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).